<VariationArchive VariationID="812471" VariationName="NM_177924.5(ASAH1):c.410_411del (p.Phe136_Tyr137insTer)" VariationType="Deletion" Accession="VCV000812471" Version="5" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-07-29" DateCreated="2020-02-16" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="800733" VariationID="812471">
      <GeneList>
        <Gene Symbol="ASAH1" FullName="N-acylsphingosine amidohydrolase 1" GeneID="427" HGNC_ID="HGNC:735" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>8p22</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="8" Accession="NC_000008.11" start="18055992" stop="18084961" display_start="18055992" display_stop="18084961" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="8" Accession="NC_000008.10" start="17913924" stop="17942506" display_start="17913924" display_stop="17942506" Strand="-" />
          </Location>
          <OMIM>613468</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_177924.5(ASAH1):c.410_411del (p.Phe136_Tyr137insTer)</Name>
      <CanonicalSPDI>NC_000008.11:18064502:ATA:A</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>8p22</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="8" Accession="NC_000008.11" start="18064503" stop="18064504" display_start="18064503" display_stop="18064504" variantLength="2" positionVCF="18064502" referenceAlleleVCF="CAT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="8" Accession="NC_000008.10" start="17922012" stop="17922013" display_start="17922012" display_stop="17922013" variantLength="2" positionVCF="17922011" referenceAlleleVCF="CAT" alternateAlleleVCF="C" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000008.10" sequenceAccession="NC_000008" sequenceVersion="10" change="g.17922013_17922014del" Assembly="GRCh37">
            <Expression>NC_000008.10:g.17922013_17922014del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000008.11" sequenceAccession="NC_000008" sequenceVersion="11" change="g.18064504_18064505del" Assembly="GRCh38">
            <Expression>NC_000008.11:g.18064504_18064505del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008985.2" sequenceAccession="NG_008985" sequenceVersion="2" change="g.25495_25496del">
            <Expression>NG_008985.2:g.25495_25496del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001127505.3" sequenceAccession="NM_001127505" sequenceVersion="3" change="c.392_393del">
            <Expression>NM_001127505.3:c.392_393del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001120977.1" sequenceAccession="NP_001120977" sequenceVersion="1" change="p.Phe130_Tyr131insTer">
            <Expression>NP_001120977.1:p.Phe130_Tyr131insTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363743.2" sequenceAccession="NM_001363743" sequenceVersion="2" change="c.215_216del">
            <Expression>NM_001363743.2:c.215_216del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350672.1" sequenceAccession="NP_001350672" sequenceVersion="1" change="p.Phe71_Tyr72insTer">
            <Expression>NP_001350672.1:p.Phe71_Tyr72insTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004315.6" sequenceAccession="NM_004315" sequenceVersion="6" change="c.458_459del">
            <Expression>NM_004315.6:c.458_459del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004306.3" sequenceAccession="NP_004306" sequenceVersion="3" change="p.Phe152_Tyr153insTer">
            <Expression>NP_004306.3:p.Phe152_Tyr153insTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_177924.5" sequenceAccession="NM_177924" sequenceVersion="5" change="c.410_411del" MANESelect="true">
            <Expression>NM_177924.5:c.410_411del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_808592.2" sequenceAccession="NP_808592" sequenceVersion="2" change="p.Phe136_Tyr137insTer">
            <Expression>NP_808592.2:p.Phe136_Tyr137insTer</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_177924.5" sequenceAccession="NM_177924" sequenceVersion="5" change="c.410_411delAT" MANESelect="true">
            <Expression>NM_177924.5:c.410_411delAT</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004315.5" sequenceAccession="NM_004315" sequenceVersion="5" change="c.458_459delAT">
            <Expression>NM_004315.5:c.458_459delAT</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1281024431" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_177924.5(ASAH1):c.410_411del (p.Phe136_Tyr137insTer) AND Farber lipogranulomatosis" Accession="RCV001003299" Version="2">
        <ClassifiedConditionList TraitSetID="43">
          <ClassifiedCondition DB="MedGen" ID="C0268255">Farber lipogranulomatosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-06-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_177924.5(ASAH1):c.410_411del (p.Phe136_Tyr137insTer) AND not provided" Accession="RCV001860533" Version="3">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-09-10" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_177924.5(ASAH1):c.410_411del (p.Phe136_Tyr137insTer) AND ASAH1-related disorders" Accession="RCV004553550" Version="1">
        <ClassifiedConditionList TraitSetID="64823">
          <ClassifiedCondition DB="MedGen" ID="CN376120">ASAH1-related disorders</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-05-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-09-10" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2020-02-16" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="DOI">10.1093/rheumatology/keu010</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24164096</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24355074</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30815900</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="43" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="14121" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Farber's lipogranulomatosis</ElementValue>
                <XRef ID="79935000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Farber's disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Farber disease</ElementValue>
                <XRef ID="333" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Farber lipogranulomatosis</ElementValue>
                <XRef ID="MONDO:0009218" DB="MONDO" />
                <XRef ID="79935000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ceramidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid ceramidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">AC deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">N-Laurylsphingosine deacylase deficiency</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FRBRL</ElementValue>
                <XRef Type="MIM" ID="228000" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of ASAH1-related disorders ranges from Farber disease (FD) to spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). Classic FD is characterized by onset in the first weeks of life of painful, progressive deformity of the major joints; palpable subcutaneous nodules of joints and mechanical pressure points; and a hoarse cry resulting from granulomas of the larynx and epiglottis. Life expectancy is usually less than two years. In the other less common types of FD, onset, severity, and primary manifestations vary. SMA-PME is characterized by early-childhood-onset progressive lower motor neuron disease manifest typically between ages three and seven years as proximal lower-extremity weakness, followed by progressive myoclonic and atonic seizures, tremulousness/tremor, and sensorineural hearing loss. Myoclonic epilepsy typically begins in late childhood after the onset of weakness and can include jerking of the upper limbs, action myoclonus, myoclonic status, and eyelid myoclonus. Other findings include generalized tremor, and cognitive decline. The time from disease onset to death from respiratory complications is usually five to 15 years.</Attribute>
                <XRef ID="NBK488189" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6426" />
                <XRef ID="6426" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29595935</ID>
                <ID Source="BookShelf">NBK488189</ID>
              </Citation>
              <XRef ID="333" DB="Orphanet" />
              <XRef ID="C0268255" DB="MedGen" />
              <XRef ID="MONDO:0009218" DB="MONDO" />
              <XRef Type="MIM" ID="228000" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="64823" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="54819" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">ASAH1-related disorders</ElementValue>
                <XRef ID="1696203" DB="Illumina Laboratory Services, Illumina" />
                <XRef ID="MONDO:0800460" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ASAH1-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ASAH1-related disorder</ElementValue>
              </Name>
              <XRef ID="CN376120" DB="MedGen" />
              <XRef ID="MONDO:0800460" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2288678" SubmissionDate="2019-07-15" DateLastUpdated="2020-02-16" DateCreated="2020-02-16">
        <ClinVarSubmissionID localKey="Pt 41.1 NM_177924.5(ASAH1):c.410_411delAT" localKeyIsSubmitted="1" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV001161382" DateUpdated="2020-02-16" DateCreated="2020-02-16" Type="SCV" Version="1" SubmitterName="Medical Affairs, Dicerna Pharmaceuticals" OrgID="507035" OrganizationCategory="other" OrgAbbreviation="MA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="DOI">10.1093/rheumatology/keu010</ID>
          </Citation>
          <Comment>Variant c.410_411delAT has been classified as pathogenic using the following rationale. Variant c.410_411delAT described in Torcoletti et al, 2014,doi:10.1093/rheumatology/keu010 was identified in a caucasian, male patient diagnosed with characteristic Farber disease symptoms consistent with Type 1 Farber disease according to Gene Reviews (https://www.ncbi.nlm.nih.gov/books/NBK488189/). Biopsy and microscopic examination of subcutaneous nodules and periarticular tissue showed an accumulation of macrophages and foamy (lipid-filled) histiocytes with broad cytoplasm arranged in clusters which is characteristic of Farber disease. Analysis of the ASAH1 gene by direct sequencing of exons and adjacent intronic sequences identified the presence in combined heterozygosis of a 2 bp deletion (c.410-411delAT) with the subsequent creation of a premature stop codon in position 137 (p.Tyr137Xfs). Functional evidence demonstrates ceramide content in cultured skin fibroblasts was markedly elevated (22.87 nM/mg; 15-fold above control), consistent with Farber disease. The patient was treated with HCST as the only available treatment option for Farber disease. All Farber symptoms resolved shortly after treatment. In addition, one unrelated patient has been identified with the same variant, Ehlert et al., 2017, DOI: 10.1002/jimd.12043 lending further support for this variant's pathogenicity.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="2" />
            </Sample>
            <Method>
              <Description>Analysis of the ASAH1 gene by direct sequencing of the exons and the adjacent intronic sequences</Description>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SecondaryFinding">no</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">painful joint swelling</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">failure to thrive</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">subcutaneous nodules</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">joint contractures</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">HSCT</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">regression of nodules</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">increased joint mobility</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">hoarse voice</ElementValue>
                </Name>
              </Trait>
            </TraitSet>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <CellLine>fibroblasts</CellLine>
              <Species TaxonomyId="9606">Human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="MethodResult">Ceramide content in cultured skin fibroblasts was markedly elevated (22.87 nM/mg; 15-fold above control), consistent with Farber disease.</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <Citation>
              <ID Source="DOI">10.1093/rheumatology/keu010</ID>
            </Citation>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ASAH1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_177924.5:c.410_411delAT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="228000" Type="MIM" />
          </Trait>
        </TraitSet>
        <Comment>Identified the presence in combined heterozygosis of a 2 bp deletion (c.410_411delAT) with the subsequent creation of a premature stop codon in position 137 (p.Tyr137Xfs) and a missense mutation (c.704G&gt;A), that leads to the substitution of amino acid glycine in position 235 with the amino acid aspartic acid (p.Gly235Asp).</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB5958214</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7692515" SubmissionDate="2023-10-19" DateLastUpdated="2023-11-20" DateCreated="2023-11-20">
        <ClinVarSubmissionID localKey="19634345|ASAH1-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004108909" DateUpdated="2023-11-20" DateCreated="2023-11-20" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The ASAH1 c.458_459delAT variant is predicted to result in premature protein termination (p.Tyr153*). Using an alternate transcript (NM_177924), this variant is also referred to as c.410_411delAT (p.Tyr137fs). This variant was reported in the compound heterozygous state in an individual with Farber disease (Patient 08, Ehlert et al. 2019. PubMed ID: 30815900). This variant is reported in 0.0019% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/8-17922011-CAT-C). Loss of function variants in ASAH1 have been reported as causative of disease. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ASAH1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_004315.5:c.458_459delAT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">ASAH1-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13915440</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4262613" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="4009720|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002238590" DateUpdated="2024-02-14" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24164096</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24355074</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30815900</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Tyr137*) in the ASAH1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ASAH1 are known to be pathogenic (PMID: 24164096, 24355074). This variant is present in population databases (no rsID available, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with Farber disease (PMID: 30815900). ClinVar contains an entry for this variant (Variation ID: 812471). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ASAH1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000008.10:g.17922012_17922013del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2288678" TraitType="Finding" MappingType="Name" MappingValue="failure to thrive" MappingRef="Preferred">
        <MedGen CUI="C2315100" Name="Failure to thrive" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288678" TraitType="Disease" MappingType="XRef" MappingValue="228000" MappingRef="OMIM">
        <MedGen CUI="C0268255" Name="Farber lipogranulomatosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7692515" TraitType="Disease" MappingType="Name" MappingValue="ASAH1-related condition" MappingRef="Preferred">
        <MedGen CUI="CN376120" Name="ASAH1-related disorders" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288678" TraitType="Finding" MappingType="Name" MappingValue="regression of nodules" MappingRef="Preferred">
        <MedGen CUI="None" Name="regression of nodules" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288678" TraitType="Finding" MappingType="Name" MappingValue="painful joint swelling" MappingRef="Preferred">
        <MedGen CUI="None" Name="painful joint swelling" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288678" TraitType="Finding" MappingType="Name" MappingValue="HSCT" MappingRef="Preferred">
        <MedGen CUI="None" Name="HSCT" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4262613" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288678" TraitType="Finding" MappingType="Name" MappingValue="joint contractures" MappingRef="Preferred">
        <MedGen CUI="C0009918" Name="Joint contracture" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288678" TraitType="Finding" MappingType="Name" MappingValue="increased joint mobility" MappingRef="Preferred">
        <MedGen CUI="C1836308" Name="Generalized joint hypermobility" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288678" TraitType="Finding" MappingType="Name" MappingValue="subcutaneous nodules" MappingRef="Preferred">
        <MedGen CUI="C0151811" Name="Subcutaneous nodule" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288678" TraitType="Finding" MappingType="Name" MappingValue="hoarse voice" MappingRef="Preferred">
        <MedGen CUI="C0019825" Name="Hoarse voice" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

